{"doi":"10.1093/oncolo/oyad002","title":"Phase Ib and Expansion Study of Gemcitabine,<i>Nab</i>-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer","abstract":"BACKGROUND: In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden. METHODS: Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination. RESULTS: Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose-limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy. CONCLUSION: In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.","journal":"The Oncologist","year":2023,"id":353626,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":7,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9545,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":644907,"name":"Anna M. Chiarella","orcid":"0000-0003-1224-9324","position":1,"is_corresponding":false},{"id":241905,"name":"James M. Cleary","orcid":"0000-0001-7213-3951","position":2,"is_corresponding":false},{"id":260771,"name":"Nora Horick","orcid":"0000-0002-4355-5853","position":3,"is_corresponding":false},{"id":43404,"name":"Colin D. Weekes","orcid":"0000-0001-6287-4334","position":4,"is_corresponding":false},{"id":634874,"name":"Thomas A. Abrams","orcid":"0000-0003-3101-1573","position":5,"is_corresponding":false},{"id":260766,"name":"Lawrence S. Blaszkowsky","orcid":"0000-0002-9437-2977","position":6,"is_corresponding":false},{"id":425195,"name":"Peter C. Enzinger","orcid":null,"position":7,"is_corresponding":false},{"id":3011,"name":"Marios Giannakis","orcid":"0000-0001-9012-6982","position":8,"is_corresponding":false},{"id":258715,"name":"Lipika Goyal","orcid":"0000-0002-9777-6221","position":9,"is_corresponding":false},{"id":6441,"name":"Jeffrey A. Meyerhardt","orcid":"0000-0002-1120-0898","position":10,"is_corresponding":false},{"id":256055,"name":"Douglas A. Rubinson","orcid":"0000-0002-5337-5231","position":11,"is_corresponding":false},{"id":333870,"name":"Matthew B. Yurgelun","orcid":"0000-0002-6184-9273","position":12,"is_corresponding":false},{"id":31805,"name":"Wolfram Goessling","orcid":"0000-0001-9972-1569","position":13,"is_corresponding":false},{"id":261639,"name":"Bruce J. Giantonio","orcid":null,"position":14,"is_corresponding":false},{"id":3726,"name":"Lauren K. Brais","orcid":"0000-0003-1069-0407","position":15,"is_corresponding":false},{"id":1100762,"name":"Victoria Germon","orcid":null,"position":16,"is_corresponding":false},{"id":1100763,"name":"Danielle Stonely","orcid":null,"position":17,"is_corresponding":false},{"id":254944,"name":"Srivatsan Raghavan","orcid":"0000-0002-5374-9918","position":18,"is_corresponding":false},{"id":662447,"name":"Basil Bakir","orcid":null,"position":19,"is_corresponding":false},{"id":732820,"name":"Koushik K. Das","orcid":"0000-0003-4533-1105","position":20,"is_corresponding":false},{"id":296416,"name":"Jason R. Pitarresi","orcid":"0000-0001-9549-4768","position":21,"is_corresponding":false},{"id":3015,"name":"Andrew J. Aguirre","orcid":"0000-0002-0701-6203","position":22,"is_corresponding":false},{"id":1100299,"name":"Michael N. Needle","orcid":"0000-0002-6182-0569","position":23,"is_corresponding":false},{"id":35288,"name":"Anil K. Rustgi","orcid":"0000-0002-6439-6919","position":24,"is_corresponding":false},{"id":56410,"name":"Brian M. Wolpin","orcid":"0000-0002-0455-1032","position":25,"is_corresponding":false},{"id":416221,"name":"Kimberly Perez","orcid":"0000-0002-5745-2994","position":0,"is_corresponding":true}],"reference_count":34,"raw_metadata":null,"created_at":"2026-07-19T01:13:02.680107Z","pmid":"36807743","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}